We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer.
The symbol included above the ‘i’ in Curis is known as a fermata. A fermata is used in written notes of musical pieces to indicate the prolongation of a note, a rest of indefinite duration, or the closing of a piece.
At Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer.
Fimepinostat, which is currently being explored in clinical studies in patients with MYC-altered diffuse large B-cell lymphoma (DLBCL) and solid tumors and has been granted Orphan Drug Designation and Fast Track Designation for the treatment of DLBCL by the U.S. Food and Drug Administration (FDA) in April 2015 and May 2018, respectively. We have begun enrollment in a Phase 1 combination study with venetoclax in DLBCL patients, including patients with translocations in both MYC and the BCL2 gene, also referred to as double-hit lymphoma, or high grade B-cell lymphoma (HGBL). We expect to report initial clinical data from this combination study in the second half of 2019.
CA-4948, which is being tested in a dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with myeloid differentiation primary response 88, or MYD88, alterations. We are currently planning to initiate a separate Phase 1 trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients.
CA-170, which is currently undergoing testing in a clinical study in patients with mesothelioma. We announced in May 2019 that we had completed our target enrollment of these patients and we expect to report initial clinical data from this study in the second half of 2019.
In addition, we are party to a collaboration with F. Hoffmann-La Roche Ltd (Roche), and Genentech Inc. (Genentech), a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge™ (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. Erivedge is approved for the treatment of advanced basal cell carcinoma (BCC).